{"name":"Lava Therapeutics","slug":"lava-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFAtWU5yR21vSHNXTWRiakR0b0xTMUlFLWVDbXktcGhFUl9DSUhFLTltTVdtQ3BIeEZ5bnVzNmc4X2dsLUw0WXF3Y2hXT3NuVl9hTEVhM09ELWdkV2JIWm9RMDZWbFA4ajNCOVZPMXN3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in LAVA Therapeutics N.V. (LVTX) - Stock Titan","headline":"If You Invested $1,000 in LAVA Therapeutics N.V. (LVTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPVWdGRTVzOWhMVlJyUkU3eXc2SjFDbl9lbm93VmphbEtwRXBybklIbjB1Njhvdk5KaXdDNkRURXdWaTlySWxaaUFuZVFjZlZPYVR4cWRNRkpzeUlKRjJsYVlUX0pIdWpsTkJRWlJLNm85ZHFZZG9ndHlSRy1xQXFNb3RWX0lpME9SOEJ1VFNCVzREWTA?oc=5","date":"2025-12-17","type":"pipeline","source":"Insightace Analytic","summary":"Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMlVsMDBXWFAtVFBJM3RRcTdaQVV1QVpyS2VWdEZTYWE2RmtqQVQtRlJDWWVONTg2SDFtNV85MHVjRUxhTkZqVEQ1S2MxczFQaF8yWEZhVFJWU25YSjVVY18tZkN5OVlxSlNockJfN0NraDVIZmxKTUdyblhDaHRFdG4tVXZwZ0h2N3VpS2tTRkNaMkNJRndZS2RNcE94OVFvYUFBLU5QZ3d4bWM0eWdZdHZobEp0MThs?oc=5","date":"2025-11-21","type":"deal","source":"Stock Titan","summary":"XOMA Royalty (Nasdaq: XOMA) completes LAVA deal; investors get $1.04 plus CVR - Stock Titan","headline":"XOMA Royalty (Nasdaq: XOMA) completes LAVA deal; investors get $1.04 plus CVR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPQzlPaG1WdW1tVUM4RXRLNXVtQlVzVUZqQmpGMWpVeHJDYWgyckNkazMzcHpuazhUa0c0aVZpZTZnUGJYa3A3elpLbkR4Nl9uX0EzZXI5QUZ1U25QOWpoQmZBcFRNZ3BWa1R0NHlqaFN1M2tOTjZJQWhXRDVTY0txc1dTTVBYWFEyNWx2LWNzMHZ1bW1KMzFyS08zcS1fWFJ1Z2g1MnI4bmxCcHVINEYyVg?oc=5","date":"2025-10-17","type":"deal","source":"Fierce Biotech","summary":"Xoma and Lava buyout cools with lower cash offer and closing conditions - Fierce Biotech","headline":"Xoma and Lava buyout cools with lower cash offer and closing conditions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFBYRUZVQmw3V0xUUUd0ZzlnS01fVFE1MHBiOUV6MzQ0TS1nQmphU0cwMFlFdFdvWGlCcHJYVzVGdmQyMUY0Xzk4VktDR0hzNGNGT05aeGVmSnRjT1RDRnJ0dmlMUjlYcnFKeDBaT2VTaVU?oc=5","date":"2025-08-21","type":"trial","source":"Oncology Pipeline","summary":"Xoma buys a cheap Mural | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Xoma buys a cheap Mural | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9odnpJelY2Z3JsQW5qRDgwU0w2UlhZOVU2akpOVUVXNTFMeGlkM0ZLaDkzb2xrcXZLTklOZDktd0hqSUZBNl83eTlUM2NVVUwyYUhr?oc=5","date":"2025-08-20","type":"pipeline","source":"FirstWord Pharma","summary":"On an M&A hot streak, XOMA snaps up Mural for about $36M - FirstWord Pharma","headline":"On an M&A hot streak, XOMA snaps up Mural for about $36M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFAwZWs5VlhLeGR6blRrZWZHLTB3ZHRRYnV0cUo0bFhuc2Y0bDZITUdxUjUyY1dCN00zMGVuMjljWDl1MTFzMl9lc056eEpkTVZTbkw4U3B2by12dlkzMUZ1M2tHR0dZaG5FcVBCeQ?oc=5","date":"2025-08-05","type":"trial","source":"Oncology Pipeline","summary":"Lava engulfed by Xoma | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Lava engulfed by Xoma | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOcFN5ZU9rbEg0Vk1XTmpETGFEVm5mdm55WGoxTUVtNEdLeDF3VjdWMEFuSVZ2S2hRRUJNZGdmeEN3WkdqdTdCdkNuZlVfcThIU25hNXFveEJuOUZ1V2wwZ2tpUmlTRzg3NnExYVoyNENiN0VTOE9wT1h5ekx2Z0NPWlprZXdmaDhsd04weVNKdDhXOVRsMFNFU2NXV3ZwbExOdklWejEzSTlLY0QxWFZn?oc=5","date":"2025-08-05","type":"pipeline","source":"statnews.com","summary":"Pharmalittle: We’re reading about Bill Gates' women’s health pledge, a Vertex pain drug failure, and more - statnews.com","headline":"Pharmalittle: We’re reading about Bill Gates' women’s health pledge, a Vertex pain drug failure, and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQTGlISTR5LW1NcmMyWnlSZEROSm1JWGlzbnpLTzNuTmJhZVpjcTdjRC1faFktT2Rjb09wRF93RnlQbmtyVW4xYTc3b3EzcTFjZEVSdW1UTFlGTzFjbV9CMXM2SXZaaUJncm9aa1JqM001cDBlWGhNMm9JT01IZDVQdks4SHZDZFBfZEtPUHdtdzVCYlQ0?oc=5","date":"2025-08-04","type":"deal","source":"BioPharma Dive","summary":"Xoma strikes deals to buy struggling biotechs HilleVax, Lava - BioPharma Dive","headline":"Xoma strikes deals to buy struggling biotechs HilleVax, Lava","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5USGZ6b1NibGFmQmQ1OW1Gd2V4b0lqYXlyNVo5WGZhLV9IT043VXFmUkxIdXBVb0NIb1YxZF9hR1I4NkozM2ZNcHJabE1OZVNuUUZR?oc=5","date":"2025-08-04","type":"pipeline","source":"FirstWord Pharma","summary":"Struggling HilleVax, LAVA find saviour in XOMA Royalty - FirstWord Pharma","headline":"Struggling HilleVax, LAVA find saviour in XOMA Royalty","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPQno1X0R3dWRDZk1mRWxUZC1SVXcwVXV4ZEh0VlJFWFpSWkd3bXdrRmhNT0F6VHI0MC1uR2swdDRrRV8wTV9vTjhhUlN5aW1mQW1wNVJtckV4T19TYl9VSFZVVlJ5eHpLTUxYN2t2Z3Flcm5qNkZKcXBNc2RCb2IzVGhNYXZBZGpla0lBQW9WdFVTNzFycTdhb0FqUVZxM2pPbjIxYW9oOEZGOWxZ?oc=5","date":"2025-08-04","type":"deal","source":"BioPharm International","summary":"XOMA Strengthens Immuno-Oncology Portfolio with Lava Royalty Deal - BioPharm International","headline":"XOMA Strengthens Immuno-Oncology Portfolio with Lava Royalty Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPRDh6YmVPQkI0YjlScGFNVFVHRHBjcHdxZkM4ck1DXzM4djVRb2lHYXItUGFFc2t3YmZYTnVMdUp3RTlMMGRsNk5hZ3pSYnNlU3NTRHc1bjdhOWVScHpJLTR2ZWdyeEp3dk95ZU4yNFVMeEJTOFViSWZkejFiczhzVHdsUXlyUzFwbW9UYkJiMkpYTFhPbldsY2FDYVhvTzBGQlUtTw?oc=5","date":"2025-08-04","type":"pipeline","source":"Fierce Biotech","summary":"Xoma goes shopping for struggling biotechs, picking up HilleVax and Lava - Fierce Biotech","headline":"Xoma goes shopping for struggling biotechs, picking up HilleVax and Lava","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}